News >

Differentiating Among EGFR Inhibitors in NSCLC

Brandon Scalea
Published: Thursday, Jan 03, 2019

Chul Kim, MD, MPH

Chul Kim, MD, MPH

The frontline setting of patients with EGFR-positive non– small cell lung cancer (NSCLC) is a crowded space, said Chul Kim, MD, MPH, but there are some considerations for thoracic oncologists to help distinguish among the available TKIs.

on Advanced Non–Small Cell Lung Cancer, Kim discussed the additions of these EGFR inhibitors to the armamentarium and how to best select therapy for these patients.

OncLive: Please provide an overview of your presentation on EGFR-mutant NSCLC.

Kim: We have seen a great number of advances made this year in the field of EGFR-positive NSCLC. Two additional EGFR TKIs were approved for the frontline treatment of these patients: osimertinib and dacomitinib. Osimertinib, a third-generation TKI, was approved based on data from the FLAURA trial. This study compared osimertinib with gefitinib or erlotinib, and osimertinib showed superior PFS versus the earlier-generation TKIs. Also remarkable about this study was that patients with central nervous system (CNS) disease at baseline benefited at a lower dose; this suggests that osimertinib is probably the way to go for patients with CNS disease.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Immunotherapeutic Strategies with the Potential to Transform Treatment for Genitourinary CancersAug 29, 20191.0
Publication Bottom Border
Border Publication